Key Takeaways NVO will report Q2 earnings on Aug. 6, with consensus EPS at $0.93 and revenues at$11.79 billion.NVO cut 2025 sales and profit guidance due to weaker U.S. demand for Wegovy and Ozempic.Competition from Eli Lilly and illegal compounded drugs is pressuring NVO's obesity drug sales.Novo Nordisk (NVO) is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.79 ...